Dept of Microbiology & Immunology Seminar - Dr. John Gordon
Hosted by Dr. Wilfred Jefferies
Allergic diseases affect a growing number of Canadian families. As a therapeutic approach intended to address their underlying immunologic basis, allergen-specific immunotherapies (SIT) can work for some allergic diseases, but they are fraught with complications, from the potential for serious adverse events to their laborious nature and therapeutic efficacy. This talk will focus on newer translational approaches to asthma therapy, including regulatory dendritic cell (DCreg) therapy. DCreg have been shown in mouse models to fully reverse the asthma phenotype and to suppress food (e.g., peanut) allergies, but also to suppress transplant rejection and autoimmune disease pathology. Human DCreg also reverse allergen sensitivity among immune cells of asthmatic individuals and, as with murine DCreg, induce differentiation of allergen-specific regulatory T cells that suppress both effector T cell and allergen-specific B cell responses. The development of additional human DCreg-based immunotherapies for applications in allergic and autoimmune diseases will be described.
|Handout-Dr. John Gordon July 12.pdf||268.56 KB|